Authors
Latest:
Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-celThe assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Adrian Kilcoyne, MD, MPH, MBA, on Adjusting Expectations for Remission Rates in Non–CAR-T Cell Therapy TrialsThe chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
Latest:
Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MDThe hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
Latest:
Handling Neuromuscular Gene Therapy at Real-World SitesNatalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis, discussed the session she chaired at MDA’s 2025 conference.
Latest:
Lowering Barriers to Access for Liso-Cel Based on New DataManali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the implications of a large scale analysis of liso-cel recipients.
Latest:
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene TherapyMatthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.
Latest:
Recognizing and Managing AEs in CAR T-Cell TherapyKelly Garvin, BSN, RN, OCN, discussed methods to communicate the benefits and risks of CAR T-cell therapy to patients and recognize AEs.
Latest:
Olivier Danos, PhD, on Enhancing Gene Therapy for DMDThe chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.
Latest:
Evaluating Lyell’s CAR-T IMPT-314 in LBCLSarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Alexey Danilov, MD, PhD, on CAR T and Bispecific Antibody Sequencing for DLBCLThe professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope discussed unanswered questions with regard to DLBCL treatment sequencing.
Latest:
Shahzad Raza, MD, on Future Plans for CAR T-Cell Therapy NXC-201 in R/R Light Chain AmyloidosisThe hematologist/oncologist at the Cleveland Clinic discussed next steps after early promising results were presented at ASCO’s 2025 meeting.
Latest:
John Murphy, PhD, on Using Gene Editing to Tackle Primary Hyperoxaluria Type 1The chief scientific officer of Arbor Biotechnologies discussed the company’s preclinical candidate ABO-101.
Latest:
Future Plans for Evaluating Spur Therapeutics’ FLT201Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital, discussed areas of interest for future study for the Gaucher disease gene therapy product.
Latest:
A Review of Autologous Stem Cell Transplantation in AmyloidosisIuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Sharif Tabebordbar, PhD, on Improving In Vivo Gene Editing for DMDThe cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.
Latest:
Alfonso Sabater, MD, PhD, on Further Research With Gene Therapy in Eye CareThe associate professor of clinical ophthalmology at University of Miami discussed the first topical application of gene therapy to the eye.
Latest:
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Surprising Associations With Neurotoxicity and Neurofilament LightThe medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.
Latest:
Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCLAlan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Using Programmable Genomic Integration to Make Edits Big and SmallJohn Finn, PhD, the chief scientific officer of Tome Biosciences, discussed the company’s pipeline for its new technology.
Latest:
The Potential of CAR T-Cell Therapy in Adult ALLEunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.
Latest:
Expanding Study Populations of Cell Therapy in Sickle Cell Disease: Michael Grimley, MDThe medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.
Latest:
Wenjun "Tia" Li, on Reducing Swelling in Mouse Models of Rheumatoid Arthritis With Gene TherapyThe PhD candidate from University of North Carolina – Chapel Hill discussed preclinical research presented at ASGCT 2023.
Latest:
Krystof Bankiewicz, MD, PhD, on GDNF Gene Therapy for Parkinson’s and AADC DeficiencyThe professor at Ohio State University and University of California – San Francisco discussed investigations with different delivery methods of GDNF gene therapy.
Latest:
Targeting Hematological Malignancies With Autologous and Allogeneic Cell TherapiesThomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.
Latest:
Carlos A. Ramos, MD, on Alternatives to T-Cell TherapyThe professor of medicine at Baylor College of Medicine discussed research with NK-T cells and alternatives to αβ T-cells.
